Oscient at market outperform by JMP

Oscient Pharmaceuticals Corp. was reiterated at a market outperform rating by JMP analyst Adam Cutler. JMP continues to track weekly Factive and Testim (Auxilium Pharmaceuticals) prescription volumes using NDC Health data. For the week ended Feb. 10, NDC reported that Factive total prescriptions were 11,132 (10,884 of which were new prescriptions), representing 1.51% of weekly prescriptions for the quinolone class of antibiotics, compared to 9,269 total prescriptions (9,091 of them new) in the previous week, representing 1.27% of weekly prescriptions from the quinolone class. Through Feb. 17, an approximate 53,896 Factive prescriptions have been written, generating an estimated $4.8 million in revenue. Total Testim scripts for the same week were 5,132 compared with 5,137 for the previous week. Shares of the Waltham, Mass., pharmaceutical company were up 16 cents, or 8.60%, at $2.02 on volume of 814,511 shares versus the three-month running average of 577,398 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.